<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; ISIS</title>
	<atom:link href="http://www.stockbloghub.com/tag/isis/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047</link>
		<comments>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047#comments</comments>
		<pubDate>Mon, 09 Jan 2012 16:44:49 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89047</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/09/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld-2/89047/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam States Preclinical Data</title>
		<link>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523</link>
		<comments>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523#comments</comments>
		<pubDate>Tue, 03 Jan 2012 19:15:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[HD]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[The Home Depot Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=89523</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc (ALNY) recently announced pre-clinical data from a trial evaluating its pipeline candidate ALN-HTT for the treatment of Huntington&#8217;s disease (HD). ALN-HTT is a novel therapeutic product that uses the potentially revolutionary RNA (ribo nucleic acid) interference (RNAi) technology. The data showed broad central nervous system (CNS) distribution and robust therapeutic silencing of the gene responsible for Huntington&#8217;s disease. Further, ALN-HTT was well tolerated in these studies. ALN-HTT is being developed in collaboration with Medtronic, Inc. (MDT) and the CHDI Foundation. Alnylam expects to file an investigational new drug application (IND) application for the candidate in 2012. Approval of the IND by the US Food &#38; Drug Administration (FDA) will allow the candidate to enter early stage clinical trials. Besides ALN-HTT, Alnylam is developing ALN-RSV01 for the treatment ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/03/alny-alnylam-states-preclinical-data/89523/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ATHN) Grading the Investment U Gurus 2011: Marc Lichtenfeld</title>
		<link>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979</link>
		<comments>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979#comments</comments>
		<pubDate>Wed, 21 Dec 2011 17:42:14 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Business Services]]></category>
		<category><![CDATA[Services]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AINV]]></category>
		<category><![CDATA[Allegheny Technologies Inc]]></category>
		<category><![CDATA[Apollo Investment Corporation]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[Athenahealth Inc]]></category>
		<category><![CDATA[ATHN]]></category>
		<category><![CDATA[ATI]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Capstead Mortgage Corporation]]></category>
		<category><![CDATA[CMO]]></category>
		<category><![CDATA[ESRX]]></category>
		<category><![CDATA[Express Scripts Inc.]]></category>
		<category><![CDATA[FAST]]></category>
		<category><![CDATA[Fastenal Company]]></category>
		<category><![CDATA[Genuine Parts Company]]></category>
		<category><![CDATA[GPC]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JOE]]></category>
		<category><![CDATA[MCK]]></category>
		<category><![CDATA[McKesson Corporation]]></category>
		<category><![CDATA[MDP]]></category>
		<category><![CDATA[MedcoHealth Solutions Inc.]]></category>
		<category><![CDATA[Meredith Corporation]]></category>
		<category><![CDATA[MHS]]></category>
		<category><![CDATA[NOC]]></category>
		<category><![CDATA[Northrop Grumman Corporation]]></category>
		<category><![CDATA[Old Republic International Corporation]]></category>
		<category><![CDATA[ORI]]></category>
		<category><![CDATA[The St. Joe Company]]></category>
		<category><![CDATA[VAR]]></category>
		<category><![CDATA[Varian Medical Systems Inc]]></category>
		<category><![CDATA[VF Corporation]]></category>
		<category><![CDATA[VFC]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88979</guid>
		<description><![CDATA[by Marc Lichtenfeld, Investment U Senior Analyst Tuesday, December 20, 2011: Issue #1668 I’m excited when my kids bring home their report cards. They’re terrific students, work hard and always bring home good grades. However, it’s always a little nerve-wracking to tabulate my own report card based on my market calls at the end of the year. The market isn’t nearly as forgiving as a second grade teacher. But nevertheless, it’s an important exercise to see what I got right and what I got wrong… what I may have been a little “early” on. So here goes: In my January 14 column, I talked about the rising trend of healthcare information technology and said two of my favorite stocks in the space were AthenaHealth (Nasdaq: ATHN) and McKesson (NYSE: MCK). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/21/athn-grading-the-investment-u-gurus-2011-marc-lichtenfeld/88979/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Still Bullish</title>
		<link>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197</link>
		<comments>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197#comments</comments>
		<pubDate>Thu, 08 Dec 2011 17:05:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=88197</guid>
		<description><![CDATA[We have maintained an Outperform rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $8.25 per share following appraisal of third quarter 2011 results. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam’s third quarter 2011 loss of 31 cents per share was narrower than the Zacks Consensus Estimate of a loss 36 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. The loss was, however, wider than the year-ago loss of $0.23 per share. Revenues for the reported quarter fell 24.9% ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/08/alny-alnylam-pharmaceuticals-analyst-still-bullish/88197/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Downgrades Shares to Neutral</title>
		<link>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746</link>
		<comments>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746#comments</comments>
		<pubDate>Wed, 30 Nov 2011 18:51:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87746</guid>
		<description><![CDATA[We recently downgraded Isis Pharmaceuticals (ISIS) to Neutral from an Outperform recommendation. Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments, and royalties. Isis Pharma’s lead pipeline candidate, Kynamro (mipomersen), is being developed for the treatment of familial hypercholesterolemia (FH). Isis Pharma has a collaboration agreement with Genzyme, a subsidiary of Sanofi-Aventis (SNY) for Kynamro. While the companies filed for EU approval of Kynamro in July, the US filing is scheduled to take place later this month. Acceptance of the US filing will trigger a $25 million milestone payment from Sanofi, most likely in early 2012. Isis Pharma and Sanofi ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/30/isis-isis-pharmaceuticals-analyst-downgrades-shares-to-neutral/87746/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral Rating on Shares</title>
		<link>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322</link>
		<comments>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322#comments</comments>
		<pubDate>Tue, 30 Aug 2011 21:15:16 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82322</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals, Inc (ALNY) with a target price of $7.00 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough technology known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this know-how to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s second quarter 2011 loss of 33 cents per share was narrower than the Zacks Consensus Estimate of a loss of 37 cents per share and the year-ago loss of 35 cents per share. Lower operating expenses led to the narrower loss despite lukewarm revenues in the quarter. Revenues for the reported quarter fell 22.6% from the prior year to $20.6 million. Revenues ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/08/30/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-rating-on-shares/82322/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Maintains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291</link>
		<comments>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291#comments</comments>
		<pubDate>Thu, 23 Jun 2011 19:34:26 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[MDT]]></category>
		<category><![CDATA[Medtronic Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77291</guid>
		<description><![CDATA[We have maintained a Neutral rating on Alnylam Pharmaceuticals Inc. (ALNY) with a target price of $9.50 per share. Alnylam Pharmaceuticals Inc. is a biopharmaceutical company developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Alnylam Pharmaceuticals Inc.’s first quarter loss of 38 cents per share was wider than the Zacks Consensus Estimate of 32 cents per share and also the year-ago loss of 29 cents. Lower revenues and higher research and development expenses led to the greater loss. Revenues for the reported quarter fell 15% from the prior year to $20.9 million but were in line with the Zacks Consensus ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/23/alny-alnylam-pharmaceuticals-analyst-maintains-neutral-on-shares/77291/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reported Loss Widens</title>
		<link>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669</link>
		<comments>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669#comments</comments>
		<pubDate>Mon, 09 May 2011 21:33:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73669</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 20 cents per share in the first quarter of 2011, wider than the year-ago loss of 10 cents and the Zacks Consensus loss Estimate of 19 cents. Revenues came in at $21.1 million, well below the Zacks Consensus Estimate of $26 million. Lower revenues and higher operating expenses led to the wider first quarter 2011 loss. Quarter in Detail Revenues, which include license fees, milestone-related payments and other payments, declined 29.3% from the year-ago period during the first quarter of 2011. Isis Pharma earned a $750,000 milestone payment from OncoGenex (OGXI) on the initiation of a phase II study with OGX-427. First quarter revenues also included revenues recognized under the company’s collaboration agreement with GlaxoSmithKline (GSK). Isis Pharma could receive another ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/09/isis-isis-pharmaceuticals-reported-loss-widens/73669/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Signs IP Deal with NYU</title>
		<link>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403</link>
		<comments>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403#comments</comments>
		<pubDate>Mon, 11 Apr 2011 03:01:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70403</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc. (ALNY) recently announced that it has received an exclusive license from the New York University (NYU) for intellectual property covering therapeutic uses of miR-33a and miR-33b to treat diseases such as atherosclerosis and metabolic syndrome. The license was obtained by Regulus Therapeutics Inc., a joint venture company formed by Alnylam in collaboration with Isis Pharmaceuticals (ISIS). In addition to the latest license, Regulus also owns fundamental patent rights related to miR-33a and miR-33b. Atherosclerosis refers to a condition in which the build-up of fatty substances like cholesterol results in the thickening of artery walls. The build-up results in the formation of atherosclerotic lesions or plaques that can slow down or stop the blood flow, ultimately causing myocardial infarction or stroke. Scientist at Regulus and NYU discovered that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/10/alny-alnylam-pharmaceuticals-signs-ip-deal-with-nyu/70403/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Analyst Retains Neutral on Shares</title>
		<link>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654</link>
		<comments>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:27:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70654</guid>
		<description><![CDATA[We recently reiterated a Neutral recommendation (Zacks #3 Rank – short-term “Hold” rating) on Isis Pharmaceuticals (ISIS). Isis Pharma is a drug discovery and development company that focuses on the development of products using ribonucleic acid (RNA)-based technologies, such as antisense. The company discovers new drugs and out-licenses them to partners for license fees, milestone payments and royalties. Isis Pharma has partnership agreements with leading pharmaceuticals companies like Genzyme (GENZ) and GlaxoSmithKline (GSK) among others. Isis Pharma also has a collaboration agreement with biotech company, Alnylam Pharmaceuticals (ALNY). Both companies have joined hands to form Regulus Therapeutics, Inc., a company that is focused on microRNA (mRNA) therapeutics. Isis Pharma focuses its research and development efforts primarily on cardiovascular, metabolic and neurodegenerative diseases and cancer while its partners are involved in ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/isis-isis-pharmaceuticals-analyst-retains-neutral-on-shares/70654/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Corporation Results Eclipsed by Sanofi-Aventis Deal</title>
		<link>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086</link>
		<comments>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086#comments</comments>
		<pubDate>Fri, 18 Feb 2011 16:44:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Chicago Rivet & Machine Company]]></category>
		<category><![CDATA[CVR]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Hospira Inc.]]></category>
		<category><![CDATA[HSP]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=67086</guid>
		<description><![CDATA[Genzyme Corporation (GENZ) reported fourth quarter earnings of 71 cents per share (excluding one-time items but including the impact of stock-based compensation expense), a couple of cents below the Zacks Consensus Estimate, but significantly above the year-earlier earnings of 17 cents. Excluding the impact of stock-based compensation expense, fourth quarter earnings came in at 82 cents, well above the year-ago period earnings of 29 cents. Results were in line with the preliminary outlook provided by the company in Jan 2011. Fourth quarter results were driven by the increase in shipments of lead product, Cerezyme, as well as Fabrazyme, contributions from other product lines and cost savings. Fourth quarter revenues increased 23% to $1.15 billion. Although revenues were slightly short of the Zacks Consensus Estimate of $1.16 billion, we were pleased ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/02/18/genz-genzyme-corporation-results-eclipsed-by-sanofi-aventis-deal/67086/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reports Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429</link>
		<comments>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429#comments</comments>
		<pubDate>Tue, 16 Nov 2010 04:57:03 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59429</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 13 cents per share in the third quarter 2010, wider than the year-ago loss of 12 cents. The higher loss was mainly due to higher operating expenses. However, third quarter loss was narrower than the Zacks Consensus Estimate of a net loss of 20 cents. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics&#8217; financial results. Quarter in Detail Third quarter revenues, which include license fees, milestone-related payments and other payments Incorporatedreased 6.9% to $28.6 million. Reported revenues exceeded the Zacks Consensus Estimate of $26 million. Revenues consist of the amortization of milestone and upfront payments received from partners like GlaxoSmithKline (GSK) and Bristol-Myers Squibb (BMY), among others. We note that the company finished ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/15/isis-isis-pharmaceuticals-reports-loss-widens/59429/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis Makes Hostile Bid for Genzyme</title>
		<link>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301</link>
		<comments>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301#comments</comments>
		<pubDate>Mon, 11 Oct 2010 15:29:00 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=54301</guid>
		<description><![CDATA[French pharma giant Sanofi-Aventis (SNY) recently went hostile with its bid to acquire biotech company Genzyme Corporation (GENZ). Sanofi has launched a tender offer for all outstanding shares of Genzyme – the offer is scheduled to expire on Dec 10. Sanofi’s offer price stands at $69 per share with the entire deal being valued at $18.5 billion. The $69 offer price represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up more than 40%. Sanofi said that it launched the hostile bid mainly due to Genzyme management’s refusal to enter into constructive discussions with Sanofi. Sanofi had initially approached Genzyme with its $69 per share ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/11/sny-sanofi-aventis-makes-hostile-bid-for-genzyme/54301/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceuticals Industries Oncology Drug Progresses</title>
		<link>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966</link>
		<comments>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966#comments</comments>
		<pubDate>Wed, 06 Oct 2010 03:45:24 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[SPA]]></category>
		<category><![CDATA[Sparton Corporation]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=53966</guid>
		<description><![CDATA[Teva Pharmaceuticals Industries Ltd. (TEVA) and OncoGenex Pharmaceuticals, Inc. (OXGI) recently announced that they have initiated a second phase III study with their oncology candidate, custirsen (OGX-011/TV-1011). The trial, SYNERGY, will evaluate custirsen as a first-line treatment for patients suffering from metastatic castrate-resistant prostate cancer (CRPC). The controlled global study will be conducted with about 800 men who will be randomized to receive either docetaxel/prednisone plus custirsen or just docetaxel/prednisone. The primary endpoint is overall survival benefit. Custirsen is already in another phase III study that was initiated in June 2010. This study, SATURN, is evaluating custirsen as a second-line therapy in patients with metastatic CRPC. Both phase III studies are being conducted under the US Food and Drug Administration’s (FDA) Special Protocol Assessment (SPA) program. Custirsen enjoys fast track ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/10/05/teva-teva-pharmaceuticals-industries-oncology-drug-progresses/53966/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(GENZ) Genzyme Rejects Sanofi-Aventis’ Aquisition Offer</title>
		<link>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857</link>
		<comments>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:25:33 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[PLX]]></category>
		<category><![CDATA[Protalix BioTherapeutics Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49857</guid>
		<description><![CDATA[Genzyme Corp. (GENZ) recently rejected Sanofi-Aventis’ (SNY) offer to acquire the company for $69 per share. Earlier in the day, Sanofi had announced its non-binding proposal to Genzyme with the all-cash transaction being valued at $18.5 billion. However, Genzyme’s board of directors rejected the offer calling it unrealistic. According to Genzyme, the offer price undervalues the company. The offer price of $69 per share represents a 38% premium over Genzyme’s share price on July 1, 2010. Rumors regarding Sanofi’s intention to acquire Genzyme have been doing the rounds since early July 2010. Since then, Genzyme’s shares have shot up 35.6%. What Does Sanofi Gain? Sanofi has a high exposure to generic risk on many of its leading franchises. The company suffered a blow recently with the entry of a generic ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/genz-genzyme-rejects-sanofi-aventis%e2%80%99-aquisition-offer/49857/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals Analyst Awards Neutral Rating</title>
		<link>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978</link>
		<comments>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978#comments</comments>
		<pubDate>Fri, 10 Sep 2010 06:05:10 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[CF]]></category>
		<category><![CDATA[CF Industries Holdings]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=50978</guid>
		<description><![CDATA[We are maintaining our Neutral recommendation on Alnylam Pharmaceuticals (ALNY) with a target price of $15. Alnylam, founded in 2002 and headquartered in Cambridge, Massachusetts, focuses on developing novel therapeutics based on a biological breakthrough known as RNA (Ribo Nucleic Acid) interference (RNAi). Alnylam’s founders pioneered the discovery of RNAi, and the company is currently utilizing this technology to build a pipeline of drug candidates for the treatment of a wide array of diseases. Key programs in the areas of respiratory syncytial virus (RSV), Parkinson’s disease (PD), cystic fibrosis (CF) and spinal cord injury round out the company’s core focus. Alnylam generates revenues from research collaborations, grants and licensing of the RNAi technology outside its core focus area. Alnylam has partnerships with several large pharmaceutical companies, such as Novartis (NVS), ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/09/alny-alnylam-pharmaceuticals-analyst-awards-neutral-rating/50978/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALNY) Alnylam Pharmaceuticals&#8217; Second Quarter Loss Down on Lower Costs</title>
		<link>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791</link>
		<comments>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791#comments</comments>
		<pubDate>Thu, 05 Aug 2010 17:22:09 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[CBST]]></category>
		<category><![CDATA[Cubist Pharmaceuticals Inc.]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=46791</guid>
		<description><![CDATA[Alnylam Pharmaceuticals Inc.’s (ALNY) second-quarter net loss of 35 cents per share was 20 cents below the loss per share in the second quarter of 2009. The Zacks Consensus Estimate indicated a loss of 30 cents per share for the reported quarter. The narrower year-over-year loss in the second quarter of 2010 was primarily attributable to the lower spend on research and development during the quarter. Revenues for the reported quarter climbed 8% to $26.6 million slightly above the Zacks Consensus Revenue Estimate of $26 million. Revenues were inclusive of $14 million from the company’s alliance with Roche HLDG LTD(RHHBY), $5.5 million from Alnylam‘s partnership with Takeda Pharmaceuticals, $1.9 million in revenues from license fee from Regulus Therapeutics Inc. pertaining to the partnership with Sanofi-Aventis (SNY), in addition to $5.2 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/08/05/alny-alnylam-pharmaceuticals-second-quarter-loss-down-on-lower-costs/46791/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(SNY) Sanofi-Aventis and Regulus Therapeutics Join To Develop micro RNA</title>
		<link>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290</link>
		<comments>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290#comments</comments>
		<pubDate>Fri, 25 Jun 2010 17:27:20 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=41290</guid>
		<description><![CDATA[Sanofi-Aventis (SNY) and Regulus Therapeutics Inc. recently joined forces to discover, develop, and commercialize microRNA (micro-RiboNucleic Acid) therapeutics. The initial focus of the alliance will be in the area of fibrosis – a group of diseases that cause scarring inside organs. MicroRNA molecules treat diseases by turning parts of genes on or off. The deal, which could be worth more than $750 million, allows Sanofi-Aventis and Regulus to collaborate on microRNA drug discovery and preclinical development in up to four microRNA targets Incorporatedluding Regulus’ lead fibrosis program targeting microRNA-21. Preclinical studies have suggested that microRNA-21 leads to the improvement of cardiac function in fibrotic impaired mice. Under the terms of the deal, Regulus – a joint venture between Alnylam Pharmaceuticals (ALNY) and Isis Pharmaceuticals, Inc. (ISIS) – would receive a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/06/25/sny-sanofi-aventis-and-regulus-therapeutics-join-to-develop-micro-rna/41290/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Reports Smaller Loss Than Expected</title>
		<link>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259</link>
		<comments>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259#comments</comments>
		<pubDate>Fri, 14 May 2010 15:55:41 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=37259</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 10 cents per share in the first quarter, well below the Zacks Consensus Estimate of a net loss of 17 cents. However, the reported quarter’s loss was higher than the year-ago period’s net loss of a cent mainly due to lower revenues and higher operating expenses. Following the adoption of a new required accounting standard, Isis is no longer including Regulus Therapeutics&#8217; financial results. Regulus has been established in collaboration with Alnylam Pharmaceuticals (ALNY). First quarter revenues, which include license fees, milestone-related payments and other payments, declined 5.2% to $29.9 million. Despite recognizing a $6 million milestone payment received from Bristol-Myers Squibb (BMY), revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/14/isis-isis-pharmaceuticals-reports-smaller-loss-than-expected/37259/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Signs Deal with GlaxoSmithKline</title>
		<link>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813</link>
		<comments>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813#comments</comments>
		<pubDate>Tue, 06 Apr 2010 03:57:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=32813</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) recently inked a major deal with GlaxoSmithKline (GSK) under which Isis ’ antisense drug discovery platform will be used for the development of new treatments for rare and serious diseases Incorporatedluding infectious and ocular diseases. Isis will receive an upfront payment of $35 million under the deal which covers up to six programs. In addition to the upfront payment, the company also stands to receive up to $20 million in milestone payments for each program up to the phase II proof-of-concept (PoC) stage. On completion of PoC studies, Glaxo has the option to license the compounds and take over the development and commercialization of the compounds. If all six programs are successful and commercialized to pre-determined sales targets, Isis could receive almost $1.5 billion in license ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/05/isis-isis-pharmaceuticals-signs-deal-with-glaxosmithkline/32813/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals and Genzyme&#8217;s Phase III Drug Data Published</title>
		<link>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930</link>
		<comments>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930#comments</comments>
		<pubDate>Wed, 17 Mar 2010 19:34:25 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LDL]]></category>
		<category><![CDATA[Lydall Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=30930</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) and Genzyme Corp. (GENZ) recently announced the publication of phase III data on mipomersen in The Lancet. The data was published from a study that was conducted in patients with homozygous familial hypercholesterolemia (hoFH). Results, which were presented at the annual American Heart Association meeting in November 2009, showed that mipomersen met its primary endpoint. The candidate achieved a 25% reduction in low-density lipoprotein – cholesterol (LDL-C) in an intent-to-treat analysis. Besides meeting the primary endpoint, the study also met each of its secondary and tertiary endpoints, which included statistically significant reductions in apolipoprotein-B, total cholesterol, non- high-density lipoprotein (HDL) cholesterol, lipoprotein (a) [Lp(a)], very low density lipoprotein-cholesterol (VLDL-C) and triglycerides. Mipomersen is Isis’ lead pipeline candidate. It is an antisense drug that targets apolipoprotein B ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/17/isis-isis-pharmaceuticals-and-genzymes-phase-iii-drug-data-published/30930/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550</link>
		<comments>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550#comments</comments>
		<pubDate>Wed, 03 Mar 2010 21:53:30 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=29550</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 16 cents per share in the fourth quarter, which was wider than the Zacks Consensus Estimate of a net loss of 11 cents. The company had reported a net loss of 8 cents in the year ago period. The wider-than-expected loss was due to higher operating expenses. For the full year, the company reported a net loss of 31 cents, well above the net loss of 10 cents reported in 2008. Once again, higher operating expenses accounted for the wider loss despite an increase in revenues. Fourth quarter revenues increased 8.8% to $32.3 million. Revenues were boosted by a $10 million sublicensing fee earned by the company in December 2009 from OncoGenex Pharmaceuticals, Inc. (OGXI), which entered into a licensing agreement ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/03/03/isis-isis-pharmaceuticals-loss-widens-2/29550/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Falls on Drug Concerns</title>
		<link>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807</link>
		<comments>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807#comments</comments>
		<pubDate>Thu, 11 Feb 2010 23:50:59 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27807</guid>
		<description><![CDATA[Shares of Isis Pharmaceuticals Inc. (ISIS) slipped more than 2% despite the company reporting positive results on its lead pipeline candidate, mipomersen. Isis and partner, Genzyme Corp. (GENZ) recently announced positive results from a phase III study. Data showed that patients suffering from heterozygous familial hypercholesterolemia (heFH) experienced a 28% reduction in low density lipoprotein (LDL) or “bad&#8221; cholesterol after 26 weeks of treatment with mipomersen. In contrast, patients receiving placebo experienced a 5% increase in cholesterol levels. Although these results were encouraging and statistically significant, concerns regarding the candidate’s safety profile surfaced with the company reporting elevations in liver transaminases, which is a sign of possible liver damage. While the company stated that the elevations were similar to that observed in earlier studies, we remain concerned that concerns regarding ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/11/isis-isis-pharmaceuticals-falls-on-drug-concerns/27807/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Expands Pipeline</title>
		<link>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201</link>
		<comments>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201#comments</comments>
		<pubDate>Tue, 19 Jan 2010 00:17:12 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[TG]]></category>
		<category><![CDATA[Tredegar Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=25201</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) is working on expanding its cardiovascular pipeline. The company recently announced that it has added a new drug, ISIS-APOCIIIRx, to its development pipeline. The candidate is being studied for the treatment of hypertriglyceridemia, or high levels of triglycerides (TG). Hypertriglyceridemia is an independent risk factor for cardiovascular disease and is also a trait of metabolic syndrome, which occurs in a large percentage of people with type II diabetes. ISIS-APOCIIIRx is the third new drug to be added to the company&#8217;s pipeline recently. Over the past few months, the company has been working on expanding its pipeline. In early December 2009, the company added two new drugs to its pipeline &#8211; ISIS-FXIRx and ISIS-SMNRx. While ISIS-FXIRx is designed to treat clotting disorders without increased risk of bleeding, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/18/isis-isis-pharmaceuticals-expands-pipeline/25201/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals Gains from Teva-OncoGenex Deal</title>
		<link>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831</link>
		<comments>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831#comments</comments>
		<pubDate>Tue, 29 Dec 2009 19:06:19 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[Eli Lilly & Company]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[LLY]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23831</guid>
		<description><![CDATA[Isis Pharmaceuticals, Inc. (ISIS) stands to benefit from the recently signed agreement between OncoGenex Pharmaceuticals (OGXI) and Teva Pharmaceutical Industries Ltd. (TEVA) for the development and commercialization of OGX-011. As Isis had co-discovered OGX-011 with OncoGenex, Isis is entitled to receive $10 million of the upfront payment made by Teva to OncoGenex. Isis will also receive 30% of the up to $370 million in milestone payments OncoGenex is eligible to receive, in addition to 5.5 &#8211; 7% royalties on all sales of OGX-011. OGX-011 is a second-generation antisense drug to inhibit cancer treatment resistance. The candidate is being developed for use as adjunct therapy to increase the effectiveness of chemotherapy. OGX-011 has completed phase II studies in prostate and lung cancer, and is scheduled to enter into two phase III ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/29/isis-isis-pharmaceuticals-gains-from-teva-oncogenex-deal/23831/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Expands Cancer Portfolio</title>
		<link>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739</link>
		<comments>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739#comments</comments>
		<pubDate>Tue, 29 Dec 2009 01:10:29 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[OGXI]]></category>
		<category><![CDATA[OncoGenex Pharmaceuticals Inc]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23739</guid>
		<description><![CDATA[In a move to expand its branded product offering, generic player Teva Pharmaceutical Industries Ltd. (TEVA) recently entered into a global license and collaboration agreement with OncoGenex Pharmaceuticals, Inc. (OGXI). Teva and OncoGenex are collaborating for the development and commercialization of OncoGenex’ late stage pipeline candidate OGX-011 which is being studied for the treatment of different types of cancer. OGX-011 has been co-discovered with Isis Pharmaceuticals (ISIS) to inhibit cancer treatment resistance. The candidate is being developed for use as adjunct therapy to increase the effectiveness of chemotherapy. OGX-011 has completed phase II studies in prostate and lung cancer and is scheduled to enter into two phase III studies in 2010. While one study will be conducted to evaluate the candidate as second-line chemotherapy in men with metastatic castrate resistant ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/28/teva-teva-pharmaceutical-expands-cancer-portfolio/23739/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ISIS) Isis Pharmaceuticals&#8217; Loss Widens</title>
		<link>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383</link>
		<comments>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383#comments</comments>
		<pubDate>Thu, 12 Nov 2009 16:16:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALNY]]></category>
		<category><![CDATA[Alnylam Pharmaceuticals Inc]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[ISIS]]></category>
		<category><![CDATA[Isis Pharmaceuticals Inc]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20383</guid>
		<description><![CDATA[Isis Pharmaceuticals Inc. (ISIS) reported a net loss of 7 cents per share in the third quarter, which was wider than the Zacks Consensus Estimate of a net loss of 5 cents. The company had reported a net income of 2 cents in the year ago period. The wider-than-expected loss was due to lower revenues and higher operating expenses. Revenues declined 9.1% to $26.8 million. Revenues include license fees, milestone-related payments and other payments. Revenues declined during the reported quarter as the company finished amortizing the revenue associated with the $50 million upfront payment received from Johnson &#38; Johnson’s (JNJ) Ortho-McNeil-Janssen in 2007. The company reported higher expenses during the quarter mainly due to the expansion of its clinical development programs Incorporatedluding additional expenses associated with the phase III clinical ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/12/isis-isis-pharmaceuticals-loss-widens/20383/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

